ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Endocyte, Inc." (ECYT) Report Updated: Jun 21, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"Endocyte, Inc." (ECYT)

Rating: Sell Volatility: Moderate
Total Grade: D Industry: Pharmaceuticals
Competitors: JNJ,SUPN,ORMP,TBPH

Stock Analysis

Rating: Monthly View

A
B
C
D
F
June July August September October November December January February March April May

Rating: Weekly View

This Week: D down no change
Last Week: D same no change
Two Weeks Ago: D up no change
service keys

"Endocyte, Inc."© quotemedia

Company Profile

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trials to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial in recurrent prostate cancer patients. The company is also developing EC1788, a folate receptor-targeted SMDC that is in preclinical development stage to treat cancer; EC1669, which is in preclinical development stage to treat inflammatory diseases; and EC0371 that is in preclinical development stage for the treatment of polycystic kidney disease. In addition, it develops Etarfolatide, a companion imaging agent for its SMDCs that target folate receptor; and EC0652, a diagnostic imaging agent targeting prostate-specific membrane antigen. The company has a collaboration agreement with Merck Sharp & Dohme Research GmbH for the development and commercialization of Vintafolide. Endocyte, Inc. was founded in 1995 and is headquartered in West Lafayette, Indiana.